CaptureSelect™ ligands offer a unique affinity purification solution based on Camelid-derived single domain [VHH] antibody fragments. These small, 14 kD affinity ligands, are the platform solution for many biopharmaceutical purification challenge and have been proven for many applications to result in a higher yield and an increased purity of the protein of interest. In addition, CaptureSelect™ ligands can be tailored to protect the protein by applying mild elution conditions. The manufacturing in yeast, without animal derived components, results in a high quality product lacking toxins and viruses.
|Regular antibodies compared to single domains from Camelids, lacking the light chain, but having similar affinity, specificity as regular antibodies.|
The proprietary CaptureSelect™ technology makes use of the uniqueness of single domain antibodies offering:
- High specificity
- High affinity
- High stability
- Ease of manufacture, non animal derived
- Easy formatting (bi/tri/quadruple heads, fusions)
- Low toxicity
- Minimized lot-to-lot variability
- Linear up-scaling
- Large lot sizes
The development of any CaptureSelect™ ligand is based on the flexibility and specificity of the mammalian immune system, enabling ligands to be designed for almost any target and selected to have specific affinity, specificity and elution profiles.
The manufacturing process of the single domain antibodies involves a proprietary yeast system and is completely free of animal derived components. Life Technologies’ facility in The Netherlands includes reactors ranging from 10L to 15.000 L reactors, micro- and ultra-filtration systems, and a clean room for final purification, allowing for rapid scale up and efficient industrial production of the affinity ligands.
Our production plant in Naarden, Netherlands has been built to an advanced engineering level, satisfying international standards for hygienic processing and for the handling of Genetically Modified Micro organisms (GMOs), and has been ISO 9001 certified since 1997.